Correspondence 0001193125-23-275717 from Inozyme Pharma, Inc. (CIK 0001693011)
Inozyme Pharma, Inc. (CIK 0001693011)
Date: Nov. 13, 2023 · CIK: 0001693011 · Accession: 0001193125-23-275717
AI Filing Summary & Sentiment
File numbers found in text: 333-275364
Letter
INOZYME PHARMA, INC.
321 Summer Street, Suite 400
Boston, MA 02210
November 13, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance, Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tyler Howes
Re: Inozyme Pharma, Inc.
Registration Statement on Form S-3
File No. 333-275364
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Inozyme Pharma, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-275364), so that it may become effective at 4:30 p.m. Eastern time on November 15, 2023, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.
Very truly yours,
INOZYME PHARMA, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP INOZYME PHARMA, INC. 321 Summer Street, Suite 400 Boston, MA 02210 November 13, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes Re: Inozyme Pharma, Inc. Registration Statement on Form S-3 File No. 333-275364 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Inozyme Pharma, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-275364), so that it may become effective at 4:30 p.m. Eastern time on November 15, 2023, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff. Very truly yours, INOZYME PHARMA, INC. By: /s/ Sanjay Subramanian Name: Sanjay Subramanian Title: Chief Financial Officer cc: Caroline Dotolo, Esq. Wilmer Cutler Pickering Hale and Dorr LLP